Evidence map›Paper›PMID 26612621›Full record

ArticleMycopathologia2016

Time-Kill Kinetics and In Vitro Antifungal Susceptibility of Non-fumigatus Aspergillus Species Isolated from Patients with Ocular Mycoses.

Yasemin Öz, Havva Gül Özdemir, Egemen Gökbolat, Nuri Kiraz, Macit Ilkit, Seyedmojtaba Seyedmousavi

Open access · hybridAbstract read
In one paragraph

Article in Mycopathologia, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
1.1field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. New thymol-derived triazole exhibits promising activity against Trichophyton rubrum.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2024
    Article
  6. Article
  7. Article
  8. Microbiology spectrum · 2023
    Article
  9. Article
  10. Article
  11. Sphingosine as a New Antifungal Agent againstInternational journal of molecular sciences · 2022
    Article
  12. Article
  13. Journal of fungi (Basel, Switzerland) · 2022
    Article
  14. Article
  15. Potential of Gallium as an Antifungal Agent.Frontiers in cellular and infection microbiology · 2019
    Article
  16. EmergingOpen forum infectious diseases · 2018
    Review
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 2 countries.

Yasemin ÖzDivision of Mycology, Department of Microbiology, Faculty of Medicine, University of Eskisehir Osmangazi, Eskisehir, Turkey.
Havva Gül ÖzdemirDivision of Ophthalmology, Medicosocial Health Center, University of Çukurova, Adana, Turkey.
Egemen GökbolatDepartment of Microbiology, Faculty of Medicine, University of Eskisehir Osmangazi, Eskisehir, Turkey.
Nuri KirazDivision of Mycology, Department of Microbiology, Cerrahpasa Faculty of Medicine, University of Istanbul, Istanbul, Turkey.
Macit IlkitDivision of Mycology, Department of Microbiology, Faculty of Medicine, University of Çukurova, Adana, Turkey.
Seyedmojtaba SeyedmousaviDepartment of Medical Microbiology and Infectious Diseases, ErasmusMC, P.O. Box 2040, 3000 CA, Rotterdam, The Netherlands. S.Seyedmousavi@gmail.com.
Cukurova University · TREskişehir Osmangazi University · TRErasmus MC · NLIstanbul University · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Aspergillus species can cause ocular morbidity and blindness, and thus, appropriate antifungal therapy is needed. We investigated the in vitro activity of itraconazole, voriconazole, posaconazole, caspofungin, anidulafungin, and amphotericin B against 14 Aspergillus isolates obtained from patients with ocular mycoses, using the CLSI reference broth microdilution methodology. In addition, time-kill assays were performed, exposing each isolate separately to 1-, 4-, and 16-fold concentrations above the minimum inhibitory concentration (MIC) of each antifungal agent. A sigmoid maximum-effect (E max) model was used to fit the time-kill curve data. The drug effect was further evaluated by measuring an increase/decrease in the killing rate of the tested isolates. The MICs of amphotericin B, itraconazole, voriconazole, and posaconazole were 0.5-1.0, 1.0, 0.5-1.0, and 0.25 µg/ml for A. brasiliensis, A. niger, and A. tubingensis isolates, respectively, and 2.0-4.0, 0.5, 1.0 for A. flavus, and 0.12-0.25 µg/ml for A. nomius isolates, respectively. A. calidoustus had the highest MIC range for the azoles (4.0-16.0 µg/ml) among all isolates tested. The minimum effective concentrations of caspofungin and anidulafungin were ≤0.03-0.5 µg/ml and ≤0.03 µg/ml for all isolates, respectively. Posaconazole demonstrated maximal killing rates (E(max) = 0.63 h(-1), r(2) = 0.71) against 14 ocular Aspergillus isolates, followed by amphotericin B (E(max) = 0.39 h(-1), r(2) = 0.87), voriconazole (E(max) = 0.35 h(-1), r(2) = 0.098), and itraconazole (E(max) = 0.01 h(-1), r(2) = 0.98). Overall, the antifungal susceptibility of the non-fumigatus Aspergillus isolates tested was species and antifungal agent dependent. Analysis of the kinetic growth assays, along with consideration of the killing rates, revealed that posaconazole was the most effective antifungal against all of the isolates.

Indexed as

Amphotericin BAnidulafunginAntifungal AgentsAspergillosisAspergillusCaspofunginEchinocandinsEyeEye Infections, FungalHumansItraconazoleLipopeptidesMicrobial Sensitivity TestsTriazolesVoriconazoleAmphotericin BAnidulafunginAntifungal AgentsCaspofunginEchinocandinsItraconazoleLipopeptidesposaconazoleTriazolesVoriconazoleAntifungal susceptibility testingNon-fumigatus Aspergillus spp.Ophthalmic mycosesTime-kill assay

Identifiers

PMID26612621
PMCPMC4786614
OpenAlexW2283298359

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.